AMENDMENTS TO THE CLAIMS

1-32. (Canceled)

33. (Previously presented)A method according to claim 34, wherein said device is wholly implanted subcutaneously in said host.

34. (Currently Amended) A method of measuring glucose in a biological fluid, comprising the steps of:

a) providing a host;

b) providing an implantable device ~~comprising a sensor capable of continuous glucose sensing, said implantable device~~ comprising a housing~~,~~ comprising a convexly protruding sensing mechanism and a ~~sensing~~ membrane ~~and a first domain; wherein said first domain comprises~~ comprising an angiogenic layer~~, wherein said sensing membrane is positioned more proximal to~~ positioned over said ~~housing~~ convexly protruding sensing mechanism, and wherein said angiogenic layer is positioned over said convexly protruding sensing mechanism to assist in the formation of vasculature adjacent to the sensing mechanism such that glucose can be provided to the sensing mechanism for continuous measurement of glucose when the device is implanted in the host ~~than said first domain; wherein said housing comprises a first portion and a protruding second portion, wherein a curvature of the protruding second portion is greater than a curvature of the first portion; wherein said first domain is located over at least a portion of said protruding second portion~~; and

c) implanting said device subcutaneously into a tissue of said host.

35-37. (Canceled)

38. (Currently Amended) A method of monitoring glucose levels, comprising:

a) providing i) a host, and ii) a device comprising a housing and a sensor capable of continuous glucose sensing, wherein said housing comprises a protruding convexly curved portion over which a sensing membrane and~~,~~ a ~~first domain~~ vascularization promotion layer are located~~;~~, and wherein the sensor is directly in contact with the protruding convexly curved portion ~~said first domain comprises a vascularization promotion layer; wherein said sensing membrane is positioned more proximal to said housing than said first domain~~; and

b) implanting said device subcutaneously.

39-40. (Canceled)

41. (Currently Amended) A method according to claim 38, wherein said ~~implant~~ device is sized and configured for being wholly implanted subcutaneously.

42. (Currently Amended) A method according to claim 41, further including the step of transmitting data from said ~~wholly implanted~~ device telemetrically.

43-47. (Canceled)

48. (Currently Amended) The method of claim 34, wherein said membrane further comprises a sensing membrane comprising ~~comprises~~ an enzyme.

49. (Previously presented)The method of claim 38, wherein said sensing membrane comprises an enzyme.

50-53. (Canceled)

54. (Currently Amended) The method of claim 34, wherein said implantable device further comprises an electrolyte phase, wherein said electrolyte phase is situated between said ~~sensing~~ membrane and said ~~sensor~~ sensing mechanism.

55. (Previously presented)The method of claim 38, wherein said device further comprises an electrolyte phase, wherein said electrolyte phase is situated between said sensing membrane and said sensor.

56. (Previously presented)The method of claim 38, further comprising implanting said device in said host under conditions such that said device measures said glucose accurately for a period of time exceeding 90 days.

57. (Previously presented)The method of claim 56, wherein said device measures said glucose accurately for a period exceeding 150 days.

58. (Previously presented) The method of claim 56, wherein said device measures said glucose accurately for a period exceeding 360 days.

59. (Previously presented) The method of claim 38, further comprising explanting said device after 90 days.

60. (Previously presented)The method of claim 59, wherein said device is explanted after 150 days.

61. (Previously presented)The method of claim 59, wherein said device is explanted after 360 days.

62. (Currently Amended) The method of claim 38, wherein said ~~first domain~~ vascularization promotion layer stabilizes over a time period to produce long-term level reflecting adequate microcirculatory delivery of glucose and oxygen to said sensor.

63. (Currently Amended) The method of claim 38, wherein said ~~first domain~~ vascularization promotion layer is formed from a material selected from the group consisting of polytetrafluoroethylene, hydrophilic polyvinylidene fluoride, mixed cellulose esters, polyvinyl chloride, polyethylene, polypropylene, Teflon, cellulose acetate, cellulose nitrate, polycarbonate, polyester, nylon, polysulphone, polymethacrylate, mixed esters of cellulose polyvinylidene difluoride, silicone, and polyacrylonitrile.

64. (Previously presented) The method of claim 38, wherein said vascular promotion layer comprises a material that has a characteristic of stimulating growth of new vascular structures by said host close to said device.

65. (Previously presented)The method of claim 38, wherein said sensor senses glucose using an enzymatic mechanism.

66. (Previously presented)The method of claim 38, wherein said sensor senses glucose using a non-enzymatic mechanism.

67. (Previously presented)The method of claim 38, wherein said sensor senses glucose using a resonance mechanism.

68. (Previously presented)The method of claim 38, wherein said sensor senses glucose using an acoustic wave mechanism.

69. (Previously presented)The method of claim 38, wherein said sensor senses glucose using an optical mechanism.

70. (Previously presented)The method of claim 34, further comprising implanting said device in said host under conditions such that said device measures said glucose accurately for a period of time exceeding 90 days.

71. (Previously presented)The method of claim 70, wherein said device measures said glucose accurately for a period exceeding 150 days.

72. (Previously presented) The method of claim 70, wherein said device measures ~~said~~ glucose accurately for a period exceeding 360 days.

73. (Previously presented) The method of claim 34, further comprising explanting said device after 90 days.

74. (Previously presented)The method of claim 73, wherein said device is explanted after 150 days.

75. (Previously presented)The method of claim 73, wherein said device is explanted after 360 days.

76. (Currently Amended) The method of claim 34, wherein said ~~first domain~~ angiogenic layer stabilizes over a time period to produce long-term level reflecting adequate microcirculatory delivery of glucose and oxygen to said ~~sensor~~ sensing region.

77. (Currently Amended) The method of claim 34, wherein said ~~first domain~~ angiogenic layer is formed from a material selected from the group consisting of polytetrafluoroethylene, hydrophilic polyvinylidene fluoride, mixed cellulose esters, polyvinyl chloride, polyethylene, Teflon, cellulose acetate, cellulose nitrate, polycarbonate, polyester, nylon, polypropylene, polymethacrylate, polysulfone, mixed esters of cellulose polyvinylidene difluoride, silicone, and polyacrylonitrile.

78. (Currently Amended) The method of claim 34, wherein said ~~first domain~~ angiogenic layer comprises a material that has a characteristic of stimulating growth of new vascular structures by said host close to said device.

79. (Currently Amended) The method of claim 34, wherein said ~~sensor~~ sensing region is configured to sense ~~senses~~ glucose using an enzymatic mechanism.

80. (Currently Amended) The method of claim 34, wherein said ~~sensor~~ sensing region is configured to sense ~~senses~~ glucose using a non-enzymatic mechanism.

81. (Currently Amended) The method of claim 34, wherein said ~~sensor~~ sensing region is configured to sense ~~senses~~ glucose using a resonance mechanism.

82. (Currently Amended) The method of claim 34, wherein said ~~sensor~~ sensing region is configured to sense ~~senses~~ glucose using an acoustic wave mechanism.

83. (Currently Amended) The method of claim 34, wherein said ~~sensor~~ sensing region is configured to sense ~~senses~~ glucose using an optical mechanism.

84-87. (Canceled)